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ABSTRACT The insufficient selectivity of drugs is a bane
of present-day therapies. This problem is significant for
antibacterial drugs, difficult for antivirals, and utterly un-
solved for anticancer drugs, which remain ineffective against
major cancers, and in addition cause severe side effects. The
problem may be solved if a therapeutic agent could have a
multitarget, combinatorial selectivity, killing, or otherwise
modifying, a cell if and only if it contains a predetermined set
of molecular targets and lacks another predetermined set of
targets. An earlier design of multitarget drugs [Varshavsky,
A. (1995) Proc. Natl. Acad. Sci. USA 92, 3663–3667] was
confined to macromolecular reagents such as proteins, with
the attendant difficulties of intracellular delivery and immu-
nogenicity. I now propose a solution to the problem of drug
selectivity that is applicable to small (<1 kDa) drugs. Two
ideas, codominant interference and antieffectors, should allow
a therapeutic regimen to possess combinatorial selectivity, in
which the number of positively and negatively sensed macro-
molecular targets can be two, three, or more. The nature of the
effector and interference moieties in a multitarget drug
determines its use: selective killing of cancer cells or, for
example, the inhibition of a neurotransmitter-inactivating
enzyme in a specific subset of the enzyme-containing cells. The
in vivo effects of such drugs would be analogous to the
outcomes of the Boolean operations ‘‘and,’’ ‘‘or,’’ and combi-
nations thereof. I discuss the logic and applications of the
antieffector and interferenceycodominance concepts, and the
attendant problem of pharmacokinetics.
The many successes of pharmacology (1, 2) do not include the
problem of cancer. Major human cancers are incurable once
they have metastasized. A few relatively rare cancers, such as
testicular carcinoma in men, Wilms’ kidney tumor, and some
leukemias in children, can often be cured through chemother-
apy but require cytotoxic treatments of a kind that cause severe
side effects and are themselves carcinogenic (2).
The main reason for the failure of cytotoxic therapies is their
insufficient selectivity for tumors. For example, treatments
with radiation or alkylating agents perturb many functions that
are common to all cells. The more selective cytotoxic drugs, for
instance, methotrexate, taxol, and etoposide, perturb the
functions of specific macromolecular targets (dihydrofolate
reductase, microtubules, and topoisomerase II), but these
targets are present in both normal and malignant cells (1, 2).
Hence the low therapeutic index of anticancer drugs and their
systemic toxicity at clinically relevant doses. Because the
mitotic activity of cells in a tumor is often lower than the
mitotic activity of normal cells in self-renewing tissues such as
the bone marrow (3), one might not have expected these drugs
to work at all—to have any preference for the killing of cancer
cells. That such preference actually exists stems in part from
the fact that tumor cells are often perturbed by their mutations
into stress-hypersensitive states. Consequently, these tumor
cells die an apoptotic death at the level of a drug-imposed
metabolic stress that induces apoptosis in some but not in most
of the organism’s normal cells (3).
With some cancers, cytotoxic therapies are ineffective from the
beginning. In other cases, these therapies yield a partial, some-
times clinically complete, but almost invariably transient remis-
sion of a cancer, in part because these treatments select for tumor
cell variants that retain tumorigenicity but are more resistant to
either apoptosis per se or a drug that induces apoptosis. Because
a significant increase in the drug or radiation dosage is precluded
by their low therapeutic index, these therapies become ineffective
when resistant clones of malignant cells, selected by a drug
treatment, present themselves as a cancer recurrence.
The failure of small cytotoxic drugs to produce a cure for
cancer has given rise to other strategies, in particular the insightful
suggestion that solid tumors can be targeted by selectively inhib-
iting neovascularization, a process that these tumors depend on
for growing to a clinically significant size (4). Another approach,
immunotoxins, involves the linking of a toxin to a ligand such as
an antibody or a growth factor that binds to a target on the surface
of tumor cells (5). Among the limitations of present-day immu-
notoxins is their incapacity, on entering a cell, to adjust their
toxicity in response to the intracellular protein composition. Yet
another approach is to enhance the ability of the immune system
to identify and selectively destroy tumor cells. The current revival
of this strategy holds the promise of a rational and curative
treatment (6). Given the complicated regimens and unsolved
problems of immunotherapies, it is clear that this and other recent
approaches (7, 8) are motivated in part by the perception that
small-drug pharmacology, so successful against bacterial infec-
tions, is unlikely to prove effective against cancer. In contrast to
this view, the premise of the strategy described in the present
work is that small anticancer drugs may become curative and free
of severe side effects if a way is found to confer on these
compounds a multitarget, combinatorial selectivity.
Most cancers are monoclonal: cell lineages of both the primary
tumor and the metastases originate from a single founder cell.
This cell is a breakthrough descendant of a cell lineage that has
been accumulating mutations for some time, often in proximity
to other neoplastic but still nonmetastatic cell lineages within an
indolent proliferative lesion such as a benign tumor (9, 10). Given
the monoclonality of a cancer, cells of both the primary tumor and
the metastases share the initial mutations that yielded the
founder cell, even if these cells differ at other loci that accumu-
lated mutations in the course of the later tumor progression.
Some of the early mutations are in genes that encode tumor
suppressors (9, 11, 12). In most cancers, both alleles of a tumor
suppressor gene are inactivated, sometimes through deletions
that encompass the gene on the two homologous chromosomes.
Thus, a monoclonal cancer, although heterogeneous genetically,
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always contains a set of founder mutations that is shared by all of
its cells.
A drug that kills a cell only if it lacks a specific macromo-
lecular target would distinguish tumor cells from many other
cells of an organism, provided that the target is a product of
a gene that had been deleted or inactivated in this cancer at the
stage of its founder cell. Such a drug may be especially selective
against cancers that lack a gene for a ubiquitously expressed
tumor suppressor, for example, the retinoblastoma (Rb) pro-
tein (11, 12). An example of the negative-target approach is the
use of a mutant adenovirus that replicates selectively in human
cancer cells lacking the tumor suppressor p53 and has been
shown to kill these cells in a model setting (8).
However, other tumor suppressors may not be expressed at
comparable levels in most cells. A drug that kills a cell if it lacks
a nonubiquitous tumor suppressor would be toxic to a subset
of normal cells as well. This problem could be reduced through
the use of a drug that is toxic only if a cell lacks two specific
macromolecules, termed negative targets. Two judiciously
chosen negative targets may, together, suffice to distinguish all
of the cancer cells from all of the organism’s normal cells. If
they do not, a third negative target that had been deleted or
rendered defective in a given cancer can be employed as well.
This strategy requires a drug that possesses the ability to kill
a cell if it lacks two or more of the predetermined targets, but
would spare a cell containing either one of these targets.
Other changes in a founder cell may involve a missense
mutation, an amplification and overexpression, an ectopic
expression, or a translocationyfusion of a specific protoonco-
gene such as, for example, Ras or Myc (9, 10, 13). A single
oncoprotein may not be a unique enough target by itself, for
reasons similar to those described above in the context of
negative targets. However, a combination of two or more
distinct oncoproteins that were either mutated or inappropri-
ately expressed in the founder cell can be employed to
formulate the unique multiprotein signature of a specific
cancer that comprises both positive and negative targets.
These considerations suggest that a conditionally cytotoxic
therapeutic regimen that is exquisitely specific for a given
cancer, and therefore would eliminate it without significant
side effects, must possess, in most cases, a multitarget, com-
binatorial (positiveynegative) selectivity of the kind defined
above. Conversely, even an informed choice of the molecular
target for a single-target drug may not suffice to define
unambiguously the cell type to be eliminated. Note that simply
combining two single-target drugs against two different targets
in a multidrug regimen would not yield a multitarget selectiv-
ity, because the two drugs together would perturb not only cells
containing both targets but also cells containing either one of
the targets.
Although the problem of insufficient selectivity is not as
acute with noncytotoxic drugs, it is relevant to them as well.
Among the multitude of examples are side effects of therapies
with antipsychotic agents. The side effects are caused in part
by the insufficient molecular specificity of drugs, which is
exemplified by the ability of antidepressants that inhibit mono-
amine oxidase to perturb other proteins as well (2). This
difficulty will continue to abate with the development of more
specific single-target inhibitors. But an entirely distinct, major,
and unsolved problem with inhibitors as drugs is the current
impossibility of restricting their action to a specific subset of
cells among those that contain the inhibitor’s target. For
example, even an exquisitely specific inhibitor of a clinically
relevant enzyme is likely to have side effects, because the
target enzyme is present, in most cases, not only in the cells
where its inhibition is clinically beneficial but also in the cells
where its inhibition is physiologically inappropriate. The
present work describes a possible solution of this problem.
A previously proposed approach to designing multitarget drugs
utilized degradation signals (degrons) and analogous signals that
exhibit the property of codominance (14, 15). As a result, this
strategy was confined to macromolecular reagents such as pro-
teins, with the attendant problems of immunogenicity, extrava-
sation, and intracellular delivery. The latter difficulty is especially
significant, because either gene-therapy or direct-delivery meth-
ods for introducing large molecules into cells work reasonably
well with cells in culture but are still inefficient with cells in an
intact organism. The challenge, then, is to attain a multitarget,
combinatorial selectivity in the setting of small (#1 kDa) drugs,
where the immunogenicity and delivery problems are less severe.
A solution, described below, invokes a modification of the earlier
idea of codominant interference (14) in conjunction with the new
concept of antieffectors. This solution is applicable to either
cytotoxic or noncytotoxic therapies.
RESULTS AND DISCUSSION
Multitarget Compounds Specific for Negative Targets: The
Concept of Codominant Interference. Previous work (14)
suggested that the property of codominance, characteristic of
degradation signals (degrons) and many other signals in
biopolymers, can be employed to design protein-based re-
agents that possess multitarget, combinatorial selectivity of the
kind defined above. Codominance refers to the ability of two
or more signals in the same molecule to function indepen-
dently and not to interfere with each other. It is shown below
that a distinct version of the interferenceycodominance (IC)
concept (14) is applicable to small (#1 kDa) compounds.
Consider a reagent containing three small moieties a, b, and
i, which can bind, respectively, to three macromolecular targets
A, B, and I. Because the moieties a, b, and i are much smaller
than the macromolecules A, B, and I, it should be possible to
arrange these moieties in the compound abi in such a way that
the binding of A or B to a or b would preclude, through steric
hindrance, the binding of moiety i to I (Fig. 1).
That the interactions of a small bipartite compound with its
two macromolecular ligands can be made mutually exclusive is
expected from basic physicochemical considerations. This has
also been demonstrated directly, in a context unrelated to the
present discussion. When lisinopril, an inhibitor of the angio-
tensin-converting enzyme (ACE), was connected, via an 11-
atom linker, to the biotin moiety, the resulting bivalent com-
pound could bind to and inhibit ACE in the absence but not
in the presence of the biotin-binding protein streptavidin (16).
Small compounds comprising two linker-connected moieties
such as cyclosporin and FK506, which are specific for two
macromolecular targets, have previously been employed as in
vivo dimerization devices, making it possible to bring together
two otherwise noninteracting proteins (17). However, the
linker moiety of these bipartite compounds was chosen to allow
simultaneous interactions with the targets, in contrast to the
mutual exclusivity of interactions in the IC approach (Fig. 1).
If the moiety i is an inhibitor of an essential cellular enzyme I,
the presence of the macromolecular targets A or B in a cell would
reduce the inhibition of enzyme I by abi, because the complexes
abi-A and abi-B would be mutually exclusive with the complex
abi-I (Fig. 1). Note that A and B are codominant in their ability
to reduce the inhibition of I by abi. Therefore, there is, formally,
no limit on the number of a, b-like competition modules that can
be used to construct an abi-like compound whose activity is
sensitive to the presence of several distinct macromolecules,
called negative targets. The fractional occupancy of the macro-
molecular targets A, B, and I by the a, b, and i moieties of abi
would be determined in part by the targets’ intracellular concen-
trations. There are also specific pharmacokinetic constraints on
the selectivity of abi, an issue discussed below.
A tabulation of the relative toxicities of abi for cells that either
lack or contain the negative targets A and B is shown in Fig. 2. It
can be seen that abi would be relatively nontoxic to three of the
four cell types and toxic exclusively to the cells that lack both A
and B (Fig. 2). Thus, the IC concept allows the construction of
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small compounds that exhibit multitarget selectivity for negative
targets. One more idea is required to accomplish the same for
positive targets and to link the two strategies.
Multitarget Compounds Specific for Positive Targets: The
Concept of Antieffectors. Consider a small compound i* that
binds to enzyme I in the vicinity of its active site, but does not
perturb the catalytic activity of I toward its physiological
substrates (Fig. 3B). Suppose further that the compound i*,
termed an antiinhibitor, was designed to interfere, sterically,
with the binding of an inhibitor i to the enzyme’s active site
while at the same time allowing the binding of physiological
substrates. One way to achieve this would be to endow either
i, or i*, or both of them with a set of chemical groups, termed
a ‘‘bump,’’ whose function is to produce steric hindrance that
makes the interactions i-I and i*-I mutually exclusive (Fig. 3 A
and B). A moiety that functions as a bump may also be
designed to enhance specific binding of either the inhibitor i or
the antiinhibitor i* to enzyme I, but this consideration is
secondary to the bump’s essential purpose.
In one application of the antiinhibitor i*, it is linked to c, a
small moiety that can bind to a macromolecular target C. The
mutual arrangement of i* and c in ci* is such that the
interactions of ci* with I and C are mutually exclusive. In the
absence of C, ci* would compete with abi for the binding to
enzyme I, thereby partially protecting I from inhibition by abi
(Fig. 3C). This protective effect of ci* would be suppressed in
the presence of its macromolecular target C (Fig. 3D). In the
logic of codominance, discussed above in the context of
negative targets, a compound bearing an antiinhibitor moiety
i* could contain more than one c-like moiety. For example, a
compound cdi*, whose moieties c and d can bind, respectively,
to the macromolecules C and D, would reduce the inhibition
of enzyme I by abi only in the absence of both C and D. Yet
another pattern of multitarget selectivity can be produced, in
this context, by separating the competition moieties c and d.
The resulting ci* and di*, if administered together with abi,
would reduce the inhibition of enzyme I by abi if just one of
the targets, C or D, is absent. As shown below, the key merit
of the antiinhibitor idea is that it allows the effect of a single
inhibitor i to be modulated by both negative and positive
macromolecular targets.
On the Difference Between Antieffectors and Antagonists.
The distinctions between substrates, inhibitors, and antiinhibi-
tors were described above. The concept of antieffectors is also
relevant to ligand-binding biopolymers other than enzymes.
For example, an agonist binds to its receptor and evokes a
physiological response. An antagonist binds to a site of the
receptor that overlaps with the agonist-binding site, does not
FIG. 1. The interferenceycodomi-
nance concept. (1–4) A small (,1
kDa) moiety i is linked to two other
small moieties, a and b. The moieties
a, b, and i are ligands of the macro-
molecules A, B, and I, respectively.
The distances between a, b, and i, and
their mutual arrangement in the tri-
partite compound abi are such that
the interaction i-I is mutually exclu-
sive with either the interaction a-A or
the interaction b-B. Specifically, the macromolecule I in its complex with the small moiety i would sterically clash with the macromolecules A or
B if either A or B is positioned to bind a or b of abi (5 and 6). In the diagram, the interactions a-A and b-B are also mutually exclusive, but this
constraint is not essential. (Note that if the interactions a-A and b-B were mutually nonexclusive, the compound abi would promote the binding
of A to B.) The codominance aspect of the IC concept allows this design to accommodate more than two of the a, b-like competition modules (not
shown). In Figs. 2–4, the i moiety is an inhibitor of an essential enzyme I. In fact, the only constraint on the identities of i and I is the requirement
for an i-I interaction to alter the functional activity of a macromolecule I. In other words, the choice of I is determined by the intended effect of
the (unsequestered) compound abi (see the main text).
FIG. 2. Multitarget selectivity of a
compound that utilizes interferencey
codominance. This diagram tabulates
the relative toxicities of the compound
abi for cells that either lack or contain
macromolecular targets A and B. The i
moiety of the compound abi (see the
legend to Fig. 1) inhibits an essential
enzyme I. The interaction i-I is mutu-
ally exclusive with the interaction a-A
and the interaction b-B, the macromol-
ecules A and B being negative targets of
abi. It is assumed that concentrations
of the targets A and B in cells that
contain at least one of them signifi-
cantly exceed the concentration of I
(see the main text). In A1 B1, A1 B2,
and A2 B1 cells, the enzyme I would
be at most partially inhibited by the i
moiety of abi, because of the compet-
ing interactions of abi with A andyor B.
By contrast, in A2 B2 cells, the bulk of
abi molecules would be available for
interaction with I, resulting in the se-
lective toxicity of abi to these cells. The
selectivity pattern of abi requires that
certain pharmacokinetic conditions
are met as well (see the main text).
Note that the physiological effects and
the uses of abi-type compounds are not
confined to cytotoxic regimens.
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activate the receptor, and in addition precludes the binding of
agonist (1, 2). By contrast, an antieffector, which would be
called, in this setting, an antiantagonist, binds to the receptor
in such a way that the receptor can still bind, and respond to,
the agonist, but cannot bind the antagonist. To this end, either
an antagonist, or an antiantagonist, or both must possess a
bump, an additional moiety described above in the context of
enzymes and antiinhibitors (Fig. 3). The idea of antieffectors
is thus distinct from that of antagonists or inhibitors and is new,
to the best of my knowledge. I am also not aware of a naturally
occurring pair of compounds that satisfy the definition of
effectorsyantieffectors in a physiologically relevant setting.
InterferenceyCodominance and Antieffector in a Regimen
That Possesses Combinatorial Selectivity. Applying the IC and
antieffector concepts together yields regimens that possess true
combinatorial selectivity, i.e., sensitivity to both negative and
positive targets. Consider a population of cells that either contain
or lack the macromolecular targets A, B, and C. Our aim is to
devise a treatment that would be toxic to cells that lack A and B
but contain C (A2 B2 C1 cells) and relatively nontoxic to the
other cell types (Fig. 4). A regimen of two compounds, abi (Fig.
3C) and ci* (Fig. 3D), has the requisite selectivity, as shown in Fig.
4, which tabulates the outcomes of this treatment for different cell
types. Specifically, in the absence of C (four cell types out of
eight), the antiinhibitor-containing ci* would compete with the
inhibitor-containing abi for binding to the essential enzyme I,
thereby reducing the inhibition of I by abi, and hence reducing the
toxicity of abi. In three other cell types, whose common property
is the presence of C and at least one of the other two targets, A
or B, the antiinhibitor-containing ci* would be largely seques-
tered by C, and hence inactive, but the inhibitor-containing abi
would be sequestered as well, by either A or B. In only one type
of cells, those that lack A and B but contain C (A2 B2 C1 cells),
is the inhibitor abi fully available for interaction with I, resulting
in higher toxicity (Fig. 4). The differences in the toxicity of abi to
different cell types would be determined by the relative stoichio-
metries and absolute concentrations of the cellular targets in-
volved (A, B, C, and I), by the affinities of the moieties a, b, c, i,
and i* for these targets, and by the pharmacokinetic properties of
abi and ci*.
Straightforward variations of the abi and ci* designs that
utilize IC and the properties of antiinhibitors would allow
selective targeting of any one of the eight cell types that differ
by the presence or absence of three macromolecular targets.
Moreover, there is no formal limit on the total number of
negative andyor positive targets that can be simultaneously
sensed by regimens that employ abi- and ci*-type compounds
bearing multiple interference moieties. Note that the cell type
selectivity of regimens such as abi 1 ci* (Fig. 4) is analogous
to the outcomes of the Boolean operations ‘‘and,’’ ‘‘or,’’ and
combinations thereof.
Stoichiometries, Affinities, and Pharmacokinetics. The se-
lectivity of the proposed compounds results from mutually
exclusive, competing interactions between individual moieties
of these compounds and their macromolecular targets (Figs.
2–4); hence, the importance of the targets’ intracellular con-
centrations, relative to each other and the enzyme I, which is
inhibited by an effector moiety of these drugs. The choice of
I is not confined to essential enzymes. The target I could be,
for instance, a DNA-binding repressor of terminal differenti-
ation, a repressor of apoptosis, or, in the example of a
noncytotoxic therapy, a neurotransmitter-inactivating enzyme.
In other words, the choice of I is determined by the intended
effect of the (unsequestered) compound abi.
The sequestration of abi- and ci*-type compounds by their
macromolecular ligands A, B, and C serves to prevent their
binding to the enzyme I (Figs. 3 and 4). Therefore, in schemes
of the type considered above, the molar concentration of I
should be significantly (if possible, considerably) lower than
the molar concentrations of A, B, and C. In addition, the
concentration of ci* in a ci* 1 abi regimen should significantly
exceed that of abi, because ci* is the sole obstacle to the
inhibition of enzyme I by abi in the A2 B2 C2 cells (Fig. 4).
It is assumed, furthermore, that the total intracellular con-
centrations of abi and ci*, bound and unbound, would remain
significantly below the concentrations of the interference
targets A, B, and C. The affinities of A, B, C, and I for the
FIG. 3. The antieffector concept. The particular case illustrated
here is that of an antiinhibitor i*, defined as a compound whose
binding to an enzyme I does not inhibit the activity of I but does
preclude the inhibition of I by an inhibitor i. In this example, the
antiinhibitor i* has the following properties. First, it binds to I in the
vicinity of the I’s active site, but does not perturb the catalytic activity
of I toward its physiological substrates. Second, i*, in its bound state,
sterically interferes with the interaction between I and its inhibitor i.
To implement the second condition, either i, or i*, or both of them
bear additional moiety, a ‘‘bump,’’ denoted by the rectangular pro-
trusions in i and i*. The function of the bump is to produce steric
hindrance that makes the interactions i-I and i*-I mutually exclusive.
The inhibitor i described here and in the main text is a competitive
inhibitor, but i could be a noncompetitive inhibitor as well. An
allosteric antiinhibitor, which functions through binding to a remote
site of enzyme I, is yet another possibility. (A) A complex of the
enzyme I with its inhibitor i. (B) A complex of I with its antiinhibitor
i*. Note that the bumps of the bound i and i* spatially overlap. (C) The
antiinhibitor i* is linked to c, a small moiety that can bind to a
macromolecular target C. The design of ci* is analogous to abi (Figs.
1 and 2), in that the interactions of ci* with I and C are mutually
exclusive. When ci* is bound to I, the inhibitor i, shown here as a part
of the compound abi (Figs. 1 and 2), is unable to bind to and inhibit
the enzyme I. (D) A complex between ci* and its macromolecular
target C. This complex, being mutually exclusive with the ci*-I
complex, reduces the ability of ci* to protect the enzyme I from
inhibition by abi.
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respective moieties of the compounds abi and ci*, and also the
targets’ intracellular locations are among the independent
parameters that can be varied in designing these compounds.
Yet another, and major, constraint on the nature and
pharmacokinetics of multitarget drugs stems from the fact that
the selectivity patterns described above (Figs. 2 and 4) may not
be observed under equilibrium conditions, where the influx of
a drug into cells equals its outflux. To illustrate one clear
difficulty, let us oversimplify and suppose that an abi-type
compound is metabolically inert, in addition to being capable
of crossing the plasma membranes and other lipid bilayers. If
abi is initially outside the cells, and if the extracellular pool of
abi (e.g., in the blood plasma) is large enough, it can be shown
that the subsequently reached equilibrium state would be
characterized by equal concentrations of the free abi in both
the A1 B1 and A2 B2 cells, thereby resulting in the equal
occupancies of the enzyme I by abi in these cells, contrary to
the pattern illustrated in Fig. 2.
By contrast, the selectivity patterns of Figs. 2 and 4 would be
observed during the initial influx of drugs into cells. Thus, one
requirement for the multitarget selectivity of abi- and ci*-type
regimens is the avoidance of equilibrium states such as the one
described above. This and related considerations indicate that
despite the logical simplicity of the proposed designs, their
implementation will have to address pharmacokinetic prob-
lems that do not necessarily arise with single-target drugs.
Selection of Targets and Construction of Multitarget Drugs.
Appropriate macromolecular targets of the A–C class (Figs. 3 and
4) are suggested by the protein composition of the tumor cells to
be eliminated. The choice of an essential intracellular enzyme I
(Figs. 2–4) is determined by the presence of I at least in tumor cells,
its physiological concentration, and the feasibility of an efficacious
inhibitor of I. Among potentially suitable enzymes for which
cell-penetrating inhibitors already exist is dihydrofolate reductase.
Its high-affinity inhibitors include methotrexate, which enters cells
through carrier-mediated pathways, and the more lipophilic tri-
metrexate, which can enter cells by diffusing through lipid bilayers
(18).
Each of the modules in the abi- and ci*-type compounds (Figs.
1–4) would bind its macromolecular target in the absence of the
other modules. Therefore, the cytotoxic i-type modules of IC-
based compounds would be similar to the stand-alone cytotoxic
drugs of today. By contrast, the interference modules of these
compounds, i.e., their a-, b-, and c-type moieties (Figs. 1–3), are
supposed to bind to their macromolecular targets but preferably
not impair them functionally. This specification of a competition
module simplifies its design in comparison to that of inhibitors,
because many sites on the target’s surface, and not just the active
site, would be acceptable.
Antiinhibitors (Fig. 3) are a new class of physiologically active
compounds. The opportunities and problems of their design are
similar to those for the interference moieties a–c (Figs. 1–3), but
there are two other difficulties as well. First, the antiinhibitor
moiety i* must bind in the vicinity of, but not at, the active site
of enzyme I. Second, the moiety i* must also bear chemical
groups (a bump) whose function is to preclude, through steric
hindrance, the binding of the inhibitor moiety i to the enzyme I
(Fig. 3).
FIG. 4. Combinatorial (positivey
negative) selectivity of a regimen that
utilizes interferenceycodominance
and antiinhibitor. The diagram tabu-
lates the relative toxicities of the com-
pound abi in the setting of a two-
compound treatment of cells that ei-
ther lack or contain the
macromolecular targets A, B, and C.
The inhibitor-containing compound
abi is described in the main text and
Figs. 1, 2, and 3C. The antiinhibitor-
containing compound ci* is described
in the main text and Fig. 3. A and B are
negative targets, in that they reduce,
through the binding to the moieties a
and b of abi, the inhibition of an
essential enzyme I by abi. C is a
positive target, in that it reduces,
through the binding to the c moiety of
ci*, the binding of ci* to enzyme I.
This results in a larger fraction of
enzyme I available for the inhibition
by abi. It is assumed that the concen-
trations of A, B, and C in cells that
contain them significantly exceed the
concentration of I (see the main text).
In all of the cell types except A2 B2
C1, the enzyme I would be at most
partially inhibited by the i moiety of
abi, because of the competing inter-
actions of abi with A andyor B, and
also because in C2 cells a fraction of
enzyme I would be protected from the
inhibition by abi through the interac-
tion of I with the antiinhibitor moiety
i* of ci*. By contrast, in A2 B2 C1
cells, the antiinhibitor-containing ci*
would be sequestered by C, whereas
abi would not be sequestered by A or
B, which are absent from these cells.
As a result, a larger fraction of the inhibitor-containing abi molecules would be available for the interaction with I, resulting in the selective toxicity
of abi to A2 B2 C1 cells. The selectivity pattern of abi requires that certain pharmacokinetic conditions are met as well (see the main text). Note
that the physiological effects and the uses of abi-type compounds are not confined to cytotoxic regimens.
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A substrate-binding cleft is not the only indentation in a
folded protein molecule. The other clefts tend to be smaller,
but they are present as well (19), and some of them may be
located next to the enzyme’s active site (Fig. 3). In addition,
even relatively flat molecular surfaces can be, in principle, the
sites of high-affinity interactions with small ligands (20). These
optimistic comments notwithstanding, the development of
antiinhibitors is certain to be a complex undertaking. As
discussed above, the pharmacokinetic aspects of the proposed
designs are also complex. Yet simplicity is good only if it works.
Single-target anticancer drugs remain unsatisfactory, in spite
of decades of immense effort. It may therefore be wise to
attempt a more complex but also more effective solution.
A recent advance in drug design, termed SAR by NMR
(structure–activity relationships by nuclear magnetic reso-
nance), provides an especially promising route to constructing
ligands for specific regions of a protein molecule (21). In this
approach, a library of small molecules is screened for binding
to an 15N-labeled protein by using NMR, which can detect
weak interactions, and in addition assigns them to specific
nitrogens of a protein, thereby identifying the site of binding.
Finding two small compounds that bind to adjacent patches of
the target protein molecule and covalently linking these com-
pounds produces a higher-affinity ligand. This powerful strat-
egy (21), which already yielded tightly binding ligands of
specific proteins, may prove sufficient for constructing the a–c
competition modules and the i* antiinhibitor modules of the
proposed designs (Figs. 1–4).
Noncytotoxic Multitarget Drugs. Many useful drugs are the
inhibitors of intracellular enzymes that are not essential for cell
viability (2). The problem of insufficient selectivity is relevant
to these drugs as well. For example, even an exquisitely specific
inhibitor of a clinically relevant enzyme is likely to have
significant side effects, because the target enzyme is present,
in most cases, not only in the cells where its inhibition is
clinically beneficial but also in the cells where its inhibition is
physiologically inappropriate. The logic of abi-type inhibitors
(Figs. 1 and 2) and ci*-type antiinhibitors (Figs. 3 and 4) is
applicable in these settings, because an informed choice of the
competition moieties a, b, and c would sharpen up the cell
selectivity of the inhibitor moiety i in the way described above
for cytotoxic drugs (Fig. 4), resulting in the inhibition of the
(nonessential) enzyme I in a predetermined subset of the
enzyme-containing cells. Note that the same considerations
apply to extracellular settings as well. The examples above are
but a glimpse of the drug-engineering vistas that are opened
up by the IC and antieffector concepts. At the same time, there
are significant pharmacokinetic constraints on the properties
of the proposed drugs, as discussed above. These constraints
are likely to complicate the implementation of the ICy
antieffector strategies.
The Problem of Drug Resistance. With small anticancer
drugs that are in use today, the macromolecular target of a
drug serves two distinct functions. First, the target is a
cell-selectivity determinant that may bias the treatment against
tumor cells. Second, the target is also a device whose inhibition
by the drug brings about the desired effect, e.g., cell death.
Consequently, when drug-resistant tumor cells, selected by a
drug treatment, present themselves as a cancer recurrence, the
necessity of employing another therapeutic agent (if such an
option exists) robs the physician of whatever cell-selectivity
advantage there was with the earlier drug.
The situation is qualitatively different with IC-based com-
pounds. Suppose that a treatment that included the drug abi
(Figs. 1 and 2) results in the appearance of abi-resistant tumor
cells that contain, for example, an altered or overproduced
enzyme I. If so, replacement of the i moiety by another small
cytotoxic moiety, specific for another essential enzyme, would
retain the cell selectivity of the new ab-containing drug. Thus,
one advantage of modularity inherent in the designs of ICy
antiinhibitor-based compounds (Figs. 1–4) lies in the separa-
tion of the effector aspect of a drug from its selectivity aspect.
As a result, once an efficacious arrangement of the selectivity
modules in abi- or ci*-type compounds has been identified, it
can be reutilized in drugs bearing effector moieties other than
i and i*.
Concluding Remarks. The above considerations are based
on the existing understanding of single-target drugs and on the
notion of steric hindrance. By introducing the new concept of
antieffectors and a modification of the previously proposed
idea of codominant interference (14), we can now attempt the
construction of small modular compounds that possess a
multitarget, combinatorial selectivity (Fig. 4). The ICy
antieffector strategies are not confined to cytotoxic therapies
and are relevant, in principle, to all pharmacological settings.
As indicated above, one expected difficulty in implementing
these strategies stems from significant pharmacokinetic con-
straints that do not necessarily arise with single-target drugs.
This work was motivated by the premise that the confine-
ment of anticancer drug research and development to single-
target compounds will prove insufficient for the task at hand,
because even the informed choices of targets for such drugs
may not define unambiguously enough the cell type to be
eliminated. The remedy, described above, is to aim for drugs
that possess qualitatively different selectivity—multitarget and
combinatorial. If this view is correct, the future ascent of
multitarget drugs may transform not only the treatment of
cancer but also approaches in other settings where the killing
or modification of undesirable cells or organelles is carried out
in the presence of nearly identical cells or organelles that must
be spared. These applications of multitarget drugs encompass
more discriminating antiviral and antifungal therapies, as well
as the selective killing of activated lymphocytes in autoimmune
diseases and the selective elimination of damaged mitochon-
dria in aging cells (14, 15). In yet another class of applications,
a noncytotoxic multitarget drug would be used to inhibit a
clinically relevant nonessential enzyme in a specific subset of
the enzyme-containing cells, thereby retaining the benefits of
inhibition while reducing its side effects.
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